Brokers Issue Forecasts for Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Disc Medicine in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($5.24) for the year. Cantor Fitzgerald has a “Overweight” rating and a $85.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

A number of other analysts have also commented on IRON. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research note on Tuesday, November 5th. Stifel Nicolaus upped their price target on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. Scotiabank raised their price objective on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research note on Tuesday. Finally, Jefferies Financial Group started coverage on Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price for the company. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine has an average rating of “Buy” and an average price target of $88.20.

Disc Medicine Stock Up 3.9 %

Shares of NASDAQ IRON opened at $60.52 on Wednesday. The business has a fifty day simple moving average of $62.82 and a 200-day simple moving average of $53.66. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -15.21 and a beta of 0.75. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Institutional Trading of Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Disc Medicine by 17.6% in the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock valued at $23,333,000 after acquiring an additional 70,983 shares in the last quarter. State Street Corp grew its holdings in Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company’s stock valued at $40,683,000 after purchasing an additional 235,115 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Disc Medicine in the second quarter valued at approximately $34,318,000. Verition Fund Management LLC acquired a new stake in shares of Disc Medicine in the third quarter worth $589,000. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after buying an additional 969,834 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Insider Buying and Selling

In related news, CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction on Monday, December 16th. The shares were sold at an average price of $66.01, for a total value of $844,333.91. Following the completion of the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at approximately $4,757,010.65. The trade was a 15.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Jacob Savage sold 9,158 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total transaction of $546,183.12. Following the completion of the sale, the insider now owns 40,405 shares of the company’s stock, valued at $2,409,754.20. This represents a 18.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,758 shares of company stock worth $5,400,990. Insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.